From Financial Modeling Prep: 2025-03-17 07:00:05

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company focusing on dermatological treatments in the clinical stage. With a ROIC of -48.01% and a WACC of 12.62%, its ratio of -3.80 indicates lower returns than cost of capital. Peers like Keros Therapeutics, Crinetics Pharmaceuticals, and Revolution Medicines show similar challenges in the biopharmaceutical sector.

Comparing Arcutis to peers, Revolution Medicines stands out with the highest ROIC to WACC ratio of -2.64, indicating more efficient return generation. Phathom Pharmaceuticals and Black Diamond Therapeutics have ratios of -2.88 and -5.33, respectively, showcasing varied levels of efficiency in generating returns relative to cost of capital. Revolution Medicines appears closest to achieving positive returns compared to peers.

Revolution Medicines leads peers in efficiency, with the highest ROIC to WACC ratio, suggesting potential for positive returns. Arcutis faces a larger gap between cost of capital and current returns. Peers like Phathom Pharmaceuticals and Black Diamond Therapeutics also exhibit challenges in generating returns relative to cost of capital.



Read more at Financial Modeling Prep:: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Financ…